Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis
- 2.2k Downloads
Antithrombin III (AT III) is an anticoagulant with anti-inflammatory properties. We assessed the benefits and harms of AT III in critically ill patients.
We searched from inception to 27 August 2015 in CENTRAL, MEDLINE, EMBASE, CAB, BIOSIS and CINAHL. We included randomized controlled trials (RCTs) irrespective of publication status, date of publication, blinding status, outcomes published or language.
We included 30 RCTs with a total of 3933 participants. The majority of included trials were at high risk of bias. Combining all trials, regardless of bias, showed no statistically significant effect of AT III on mortality (RR 0.95, 95 % CI 0.88–1.03, I 2 = 0 %, fixed-effect model, 29 trials, 3882 participants). Among those with severe sepsis and disseminated intravascular coagulation (DIC), AT III showed no impact on mortality (RR 0.95, 95 % Cl 0.88–1.03, I 2 = 0 %, fixed-effect model, 12 trials, 2858 participants). We carried out multiple subgroup and sensitivity analyses to assess the benefits and harms of AT III and to examine the impact of risk of bias. AT III significantly increased bleeding events (RR 1.58, 95 % CI 1.35–1.84, I 2 = 0 %, fixed-effect model, 11 trials, 3019 participants). However, for all other outcome measures and analyses, the results did not reach statistical significance.
There is insufficient evidence to support AT III substitution in any category of critically ill participants including those with sepsis and DIC. AT III did not show an impact on mortality, but increased the risk of bleeding.
KeywordsAntithrombin III Bleeding DIC Multi organ failure Sepsis Septic shock
Compliance with ethical standards
Conflicts of interest
Mikkel Allingstrup, Frederikke B. Ravn, Ann Merete Møller and Arash Afshari declare that there are no conflicts of interest. Jørn Wetterslev declares that he is a member of the task force on TSA at Copenhagen Trial Unit developing and programming TSA.
- 13.Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. http://www.cochrane-handbook.org. Accessed March 2011
- 14.Afshari A, Wetterslev J, Brok J, Møller A (2008) Antithrombin III for critically ill patients. Cochrane Database Syst Rev 16(3):5370Google Scholar
- 15.The Cochrane Collaboration (2014) Review Manager (RevMan), version 5.3.5. The Nordic Cochrane Centre, CopenhagenGoogle Scholar
- 16.Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C (2011) User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark, pp 1–115. http://www.ctu.dk/tsa/files/tsa_manual.pdf
- 18.Balk RA, Bedrosian C, McCormick L et al (1995) Prospective double blind placebo-controlled trial of ATIII substitution in sepsis. Intensive Care Med 21:17Google Scholar
- 23.Eisele B, Lamy M, Thijs LG et al (1998) Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 24:663–672CrossRefPubMedGoogle Scholar
- 36.Muntean W, Rossegger H (1989) Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). Thromb Haemost 62:288Google Scholar
- 39.Palareti G, Legnani C, Coccheri S et al (1995) Laboratory effects of antithrombin-III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support—a controlled, double-blind, randomized multicenter study. Thromb Haemost 73:1251Google Scholar
- 42.Schuster HP, Eisele B, Keinecke HO et al (1997) S-AT III study: antithrombin III in patients with sepsis. Intensive Care Med 23(Suppl 1):76Google Scholar
- 44.Vorobyeva N, Neporada E, Turundaevskaia O, Mel’nikova G (2007) Place of antithrombin III concentrate in the intensive care of disseminated intravascular coagulation. Anesteziol Reanimatol 2:42–44Google Scholar
- 47.D’Angelo A, Valsecchi L (2015) High-dose antithrombin supplementation in early pre-eclampsia: a double-blind, placebo controlled study (on behalf of the AT III-EPAS study group). http://abstract.mci-group.com/cgi-bin/mc/printabs.pl?APP=ISTH2009ABS-abstract&TEMPLATE=&keyf=0771&showHide=show&client. Accessed 21 April 2015